Maynard Um
-
-
-
-
-
-
-
Fate Therapeutics to present CAR T-cell therapy data at medical conferences
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $2.50 at Wells Fargo
-
-
-
-
-
-
-
Fate Therapeutics (FATE) announces phase 1 data presentation on FT819
-
-
-
-
-
-
-
Biotech outlook for 2025: Stifel
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q2 EPS by 13c
-
448,020 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

